About This Deal
AbbVie acquired Landos Biopharma, Inc., a transaction completed in June 2024.
Landos Biopharma, Inc. operates in Immunology (IBD), is based in Blacksburg, Virginia. AbbVie completed its acquisition of Landos Biopharma, adding the first-in-class investigational asset ABBV-113 (NX-13) to its pipeline. ABBV-113 offers a novel oral approach to treating ulcerative colitis (UC) and Crohn's disease (CD).
Adds a novel first-in-class oral immunology asset for inflammatory bowel disease to AbbVie's pipeline.
Deal Terms
Acquirer
AbbVie
Target
Landos Biopharma, Inc.
Value
Not disclosed
Date
June 2024
Type
Full acquisition
Status
Ready
Transaction Details
Target HQ
Blacksburg, Virginia
Segment
Immunology (IBD)
Closed
June 1, 2024
Advisors
Advisory firms were not disclosed for this transaction.
Related Deals & Entities
Sources:
Press release ↗
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.